AtriCure: The Profitability Inflection Is Real — The Price Is the Question

AtriCure has done the thing growth companies are supposed to do. After years of bleeding cash to build its surgical device franchises, the company turned profitable in 2026, generating $9 million in net income during the second quarter — a flip from a $6.2 million loss at the same time last year. Revenue is growing 13% annually. Gross margins sit at 77.2%. Free cash flow surged 255% year over year. The company holds $168 million in cash with minimal debt.

The stock responded by climbing roughly 82% over the past four months and more than 35% year to date, pushing AtriCure to a $2.7 billion market cap and a price near $54 per share.

That improvement is real. The question for anyone watching the chart climb this steeply is whether the number is too.

From Burn to Profit — The Turning Point

AtriCure makes surgical tools for treating atrial fibrillation, the world's most common cardiac arrhythmia, which affects roughly 12 million Americans. Unlike companies that fight over catheter-based procedures inside the heart — the battleground where Boston Scientific and J&J are pushing pulsed field ablation, or PFA — AtriCure operates where the surgeon's hand works: during open-heart and minimally invasive cardiac surgery. Three product franchises drive the business.

Appendage management, the largest at $51.6 million in Q2 revenue, is built around the AtriClip, a mechanical clip that closes off the left atrial appendage where most afib-related clots form. The AtriClip is the most widely implanted surgical device of its kind globally, with over 100,000 units sold over its lifetime. Newer Mini versions now represent 45% of appendage management revenue.

Open ablation ($40.9 million in Q2) delivers the tools surgeons use to create scar tissue patterns that block erratic heart rhythms. Pain management ($27.1 million in Q2) uses cryo-probes to temporarily freeze nerves after surgery — the cryoSPHERE MAX probe alone accounts for roughly 75% of U.S. pain management revenue and grew 28% year over year.

What changed in 2026 is not the business model but its operating leverage. AtriCure sold $534.5 million worth of devices in all of 2025 and lost $11.4 million. Full-year 2026 guidance calls for $602-$610 million in revenue — only a 13-14% increase — but adjusted EBITDA of $85-$89 million and positive net income per share of $0.05-$0.13. That is not a revenue explosion. It's a margin expansion story. The company crossed the inflection point where each additional dollar of revenue stops being swallowed by operating expense and starts flowing to the bottom line.

The Multiple Question

Here is where the story becomes harder to sell. AtriCure trades at roughly 4.8 times trailing sales. A $2.7 billion company on $565 million in annualized revenue — even with 77% gross margins and a genuine path to sustained profitability — commands a premium. Forward earnings aren't meaningful yet; the first full year of positive GAAP earnings is still a projection.

The competitor article that sparked this research pegged a "fair value" around $47. I don't put much weight on single-model fair value targets for a company this close to its profitability inflection point. The model assumptions shift dramatically depending on whether you believe AtriCure's margin expansion continues or normalizes. What matters more than any point estimate is understanding what the current price requires.

At $54, the market is pricing AtriCure as if margin expansion is not only happening but accelerating. The stock has already rewarded the $11 million swing from net loss to net income in a single quarter. The remaining upside depends on two things: sustained mid-teens revenue growth through management's stated $1 billion revenue target by 2030, and the EBITDA margin continuing to widen past the 15% range it projected for full-year 2026.

That is a plausible trajectory. It is not a guaranteed one.

What Could Go Sideways

Three factors stand out.

Competition in AtriClip territory.Management acknowledged on the earnings call that new entrants are entering the appendage management market. They defended their position citing the AtriClip's clinical track record and surgeon relationships — a fair argument for now. But being the incumbent and being defensible are different things. AtriClip is 50% of AtriCure's revenue. If a competitive device gains traction, the company's largest growth engine slows.

Minimally invasive ablation is under pressure.This business line, once a strategic priority, is being squeezed by the industry's shift toward catheter-based PFA procedures. Management said referral patterns for hybrid procedures have stabilized at a small subset of accounts. Stabilized is not growing. This segment isn't dragging the company down — yet — but it is a reminder that the broader market is evolving away from surgery, and AtriCure's entire business depends on surgeons operating on patients.

The stock is overbought. An RSI above 78 is deep into stretched territory. The 50-day moving average sits at $40.5; the stock is trading $13 above it. None of these numbers change the business. But they do mean the market has already done its pricing. The investor who buys today is paying for the $1 billion 2030 vision before it has been proven quarter by quarter.

The Clinical Wildcard

There is one development that could change how the entire market sizes AtriCure's opportunity: the BoxX-NoAF clinical trial. AtriCure is studying whether routine surgical ablation and LAA closure benefit cardiac surgery patients who don't currently have atrial fibrillation. If the answer is yes, the company isn't just selling to today's afib population — it's creating an incremental market by convincing surgeons to prevent the condition in every patient who comes through the operating room.

The trial has enrolled over 500 of its 960 target patients and is ahead of schedule, with data readouts expected in the first half of 2027. That timeline is material. Positive results would justify the current multiple and potentially expand it. Neutral or negative results remove a key piece of the growth narrative.

AtriCure also has the LEAPS trial (6,500+ patients enrolled) studying LAA closure for stroke reduction in patients without afib, and early trials of the PSA EnCompass clamp for percutaneous applications. These are optionality, not revenue — but they are optionality that could reframe the market opportunity.

The Bottom Line

AtriCure is a company that genuinely earned its move. The transition from cash burn to cash generation, supported by a dominant position in surgical afib treatment and 77% gross margins, is the kind of inflection that separates durable medtech businesses from perpetual growth traps.

But the stock has already done the work of pricing that inflection in. The 82% rally over four months means the gap between current price and reasonable value has narrowed considerably. The business is no longer the underdog. The question for an investor is no longer whether AtriCure can turn a profit — it already did — but whether it can sustain that trajectory through competitive pressure and an industry that's slowly drifting toward catheter-based treatments.

For someone with no position, chasing a 35% YTD gainer at 4.8x sales with just-turned profitability requires conviction in the $1 billion by 2030 target and faith that the BoxX-NoAF trial opens a bigger door. That conviction is earned, not assumed. The patient approach would be to wait for a pullback that restores the margin of safety, or to watch the next two earnings reports and the 2027 trial data before deciding the price is right.

The market doesn't reward patience, but it punishes enthusiasm that arrives late.